Avalyn Pharma has announced the pricing of its upsized initial public offering (IPO) at $18 per share, aiming to raise a total of $300 million. The offering reflects an increase in the number of shares available to investors, indicating strong demand for the company's stock. The proceeds from the IPO are expected to be utilized to advance Avalyn Pharma's clinical programs and support its operational growth. The shares are set to be listed on a major stock exchange, further enhancing the company's visibility in the market.
Related Articles
Don't miss out on breaking stories and in-depth articles.